KR20230035281A - Composition enriched in polar lipids fraction from whey and uses thereof - Google Patents
Composition enriched in polar lipids fraction from whey and uses thereof Download PDFInfo
- Publication number
- KR20230035281A KR20230035281A KR1020230024599A KR20230024599A KR20230035281A KR 20230035281 A KR20230035281 A KR 20230035281A KR 1020230024599 A KR1020230024599 A KR 1020230024599A KR 20230024599 A KR20230024599 A KR 20230024599A KR 20230035281 A KR20230035281 A KR 20230035281A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- weight
- whey
- alcohol
- derived
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 99
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 82
- 102000007544 Whey Proteins Human genes 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 239000005862 Whey Substances 0.000 title claims abstract description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000012141 concentrate Substances 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 28
- 235000021119 whey protein Nutrition 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 235000000346 sugar Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 16
- 239000008101 lactose Substances 0.000 claims description 16
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 16
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 14
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 235000015096 spirit Nutrition 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 230000007413 intestinal health Effects 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 238000004945 emulsification Methods 0.000 abstract description 4
- 235000014121 butter Nutrition 0.000 description 14
- 235000013336 milk Nutrition 0.000 description 13
- 239000008267 milk Substances 0.000 description 13
- 210000004080 milk Anatomy 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 235000013351 cheese Nutrition 0.000 description 5
- 235000021243 milk fat Nutrition 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- -1 sphingomyelin (SM) Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000252794 Sphinx Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
- A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 유청 유래 극성지질 농축 분획 조성물, 이의 제조방법 및 이의 용도에 관한 것이다.The present invention relates to a whey-derived polar lipid enriched fraction composition, a method for preparing the same, and a use thereof.
인간을 포함한 포유류는 유지방구(fat milk globules)의 막(membrane)의 형태로 지질 영양분을 전달하며, 이러한 유지방구 막의 구성성분(components)으로 극성지질(polar lipids), 특히 인지질(phospholipids) 및 스핑고지질(sphingolipids), 콜레스테롤(Cholesterol) 등의 복합지질 성분이 알려져 있다. 이들 유지방구막 복합지질 성분에 대하여 여러 제조방법 및 생리 기능성이 알려져 있다.Mammals, including humans, deliver lipid nutrients in the form of membranes of fat milk globules, and polar lipids, especially phospholipids and sphinxes, are components of these membranes. Complex lipid components such as sphingolipids and cholesterol are known. Various preparation methods and physiological functions are known for these milk fat membrane composite lipid components.
EP1814399에서는 버터 및 버터오일 제조 시에 상전이 과정을 거쳐 베타세럼으로 통칭되는 인지질 등 복합지질 농축 분획을 얻는 과정과 이를 영유아식 용도로 사용하는 것에 대하여 기술하였다. 그러나 상기 문헌에서 극성지방 농축물을 얻는 방법으로 제시한 초임계 이산화탄소 이용법은 생산 단가가 비싸고, 비극성의 성질을 가지는 초임계 유체의 성질로 인하여 물 혹은 에탄올을 혼합하여 아임계 등의 운용조건을 구현해야 하는 단점이 있었다. EP1814399 describes the process of obtaining complex lipid-rich fractions, such as phospholipids commonly referred to as beta serum, through a phase transition process in the manufacture of butter and butter oil, and their use for infant food. However, the method of using supercritical carbon dioxide presented as a method of obtaining a polar fat concentrate in the above literature is expensive to produce, and due to the nature of a non-polar supercritical fluid, water or ethanol is mixed to realize operating conditions such as subcritical. There were downsides that had to be done.
또한, WO2003/071875에서 유청으로부터 스핑고지질 등의 극성지질을 농축하는 방법으로 한외여과 및 정용여과 방법이 제시된 바 있다. 그러나 해당 방법은 농축할 수 있는 극성지질의 함량이 제한적이고, 필수적으로 단백질이 과량 포함되어 소재의 이용에 필연적으로 파우더 형태를 거쳐야 하며, 또한 수상의 성분과 유상의 성분이 섞여 있어, 목적에 맞게 가공 시 수상 이용 시에는 유상의 성분이 적용을 어렵게 하고, 유상 이용 시에는 수상의 성분이 제품 적용을 어렵게 하는 단점을 가지고 있었다.In addition, WO2003/071875 has proposed ultrafiltration and diafiltration methods as a method for concentrating polar lipids such as sphingolipids from whey. However, the method has a limited polar lipid content that can be concentrated, and inevitably contains an excessive amount of protein, so the material must be in the form of powder for use, and the water phase and oil phase components are mixed, making it suitable for the purpose. When using the water phase during processing, the oil phase ingredients make it difficult to apply, and when using the oil phase, the water phase ingredients make it difficult to apply the product.
또한, WO2008/009636에서 파스퇴르화 우유 크림으로부터 한외여과 및 정용여과 혹은 한외여과를 통하여 인지질 형태의 극성지질을 농축하는 방법이 개시되었으나, 해당 방법을 통한 극성지질 농축물은 필연적으로 유당 및 카제인을 다량 함유하게 되어, 극성지질을 높은 함량으로 농축 시 극성 지질과 비극성 지질 그리고 수성 성분이 서로 부조화하여 층분리 및 침전 등의 문제를 발생시켰다.In addition, WO2008/009636 discloses a method for concentrating polar lipids in the form of phospholipids from pasteurized milk cream through ultrafiltration, diafiltration, or ultrafiltration, but the polar lipid concentrate through the method inevitably contains large amounts of lactose and casein. When the polar lipid is concentrated to a high content, the polar lipid, the non-polar lipid, and the aqueous component are incompatible with each other, causing problems such as layer separation and precipitation.
또한, WO2009/066685에서는 우유 유래 극성지질을 경구섭취 혹은 피부도포를 통하여 신경말단의 감각을 개선하는 용도로 사용하는 방법이 개시되었으나, 구체적으로 버터유래의 극성지질 조성물이 개시되었다. 또한, 일본 특허 JP2003/070669에서는 유청 유래 인지질 조성물이 로타바이러스 예방에 쓰일 수 있다는 것이 밝혔으나, 인지질 함량이 3%를 넘지 못하였다. In addition, WO2009/066685 discloses a method of using milk-derived polar lipids for the purpose of improving the sensation of nerve terminals through oral intake or skin application, but specifically, a butter-derived polar lipid composition is disclosed. In addition, Japanese patent JP2003/070669 revealed that a whey-derived phospholipid composition could be used for preventing rotavirus, but the phospholipid content did not exceed 3%.
본 발명은 기존 버터유 제조공정 부산물로부터 제조된 유지방구막 지질 농축물이 유당 및 카제인으로 인하여 표준화가 어렵고, 극성지질 성분 농축시 필연적으로 수상용해 성분이 다량 포함되는 단점을 해결하는 것을 목적으로 한다.The purpose of the present invention is to solve the disadvantages that the milk fat membrane lipid concentrate prepared from by-products of the existing butter oil manufacturing process is difficult to standardize due to lactose and casein, and that a large amount of water-soluble components are inevitably included when polar lipid components are concentrated. .
구체적으로, 본 발명은 유화성 및 생리 기능성을 극대화한 안정한 형태의 고농축 인지질 조성물을 제공하는 것을 목적으로 한다.Specifically, an object of the present invention is to provide a highly concentrated phospholipid composition in a stable form with maximized emulsification and physiological functionality.
또한, 본 발명은 높은 인지질 함량을 지니고, 기존 밀크 레시틴(버터 유래)에 대비하여 간편한 음용성을 갖는 식품을 제공하는 것을 목적으로 한다.In addition, an object of the present invention is to provide a food having a high phospholipid content and easy drinking compared to existing milk lecithin (derived from butter).
상기한 목적을 달성하기 위해, 본 발명은 농축 유청 단백질로부터 유래하는 단일상의 조성물로서, 물을 포함하는 주정으로 상기 농축 유청 단백질을 처리하여 얻어진 분획으로부터 유래하고, 총 지질의 함량이, 조성물의 건조물 중량을 기준으로 90 중량% 이상이고, 인지질 함량이 총 지질 중량을 기준으로 35 중량% 이상인 유청 유래 극성지질 농축 분획 조성물을 제공한다.In order to achieve the above object, the present invention is a single-phase composition derived from concentrated whey protein, derived from a fraction obtained by treating the concentrated whey protein with an alcohol containing water, the total lipid content is a dry matter of the composition Provided is a whey-derived polar lipid-enriched fraction composition having at least 90% by weight and a phospholipid content of at least 35% by weight based on the total lipid weight.
상기 조성물은, 조성물의 건조물 중량을 기준으로 1.35 중량% 이하의 환원당을 더 포함하는 것이 바람직하다.Preferably, the composition further comprises a reducing sugar of 1.35% by weight or less based on the dry weight of the composition.
상기 조성물은, 조성물의 건조물 중량을 기준으로 1 내지 10 중량%의 콜레스테롤을 더 포함하는 것이 바람직하다.Preferably, the composition further comprises 1 to 10% by weight of cholesterol based on the dry weight of the composition.
상기 조성물은, 조성물의 건조물 중량을 기준으로 1 내지 10 중량%의 단백질을 더 포함하는 것이 바람직하다.Preferably, the composition further comprises 1 to 10% by weight of protein based on the dry weight of the composition.
상기 인지질은 포스파티딜콜린, 포스파티딜에탄올아민 또는 스핑고미엘린을 포함하고, 포스파티딜콜린 1 중량부에 대하여 포스파티딜에탄올아민 0.5 내지 1.5 중량부, 스핑고미엘린 0.5 내지 1.5 중량부로 포함하는 것이 바람직하다.The phospholipid includes phosphatidylcholine, phosphatidylethanolamine, or sphingomyelin, and preferably includes 0.5 to 1.5 parts by weight of phosphatidylethanolamine and 0.5 to 1.5 parts by weight of sphingomyelin based on 1 part by weight of phosphatidylcholine.
본 발명의 다른 측면은 Another aspect of the present invention is
1) 유청액을 농축하여 농축 유청 단백질을 제조하는 단계; 1) Concentrating the whey liquid to produce concentrated whey protein;
2) 물을 포함하는 주정으로 상기 농축 유청 단백질을 처리한 다음 주정 용물과 주정 불용물로 분리하는 단계; 및2) treating the concentrated whey protein with water-containing alcohol and then separating into alcohol-soluble and alcohol-insoluble substances; and
3) 상기 주정 용물로부터 에탄올과 수분을 제거하여 유청 유래 극성지질 분획 농축물을 얻는 단계;를 포함하는 상기 유청 유래 극성지질 농축 분획 조성물의 제조방법을 제공한다.3) obtaining a whey-derived polar lipid fraction concentrate by removing ethanol and water from the alcohol solution;
본 발명의 또 다른 측면은 상기 조성물의 식품, 화장품, 의약품, 첨가제 등의 용도를 제공한다.Another aspect of the present invention provides the use of the composition in foods, cosmetics, pharmaceuticals, additives and the like.
본 발명에 따르면 유지방구 막의 지질성분이 안정한 조성물을 제조할 수 있다. 구체적으로 기존 버터유 제조공정 부산물로부터 제조된 유지방구막 극성지질 농축물이 유당 및 카제인으로 인하여 표준화가 어렵고, 극성지질 성분 농축시 필연적으로 수상용해 성분이 다량 포함되는 단점을 해결하여 유화성 및 생리 기능성을 극대화한 안정한 형태의 유청 유래 극성지질 농축 분획 조성물을 제조할 수 있다.According to the present invention, it is possible to prepare a composition in which the lipid component of the milk fat cell membrane is stable. Specifically, it is difficult to standardize polar lipid concentrates of milk fat membranes prepared from by-products of the existing butter oil manufacturing process due to lactose and casein, and inevitably contains a large amount of aqueous phase-soluble components when polar lipid components are concentrated. It is possible to prepare a whey-derived polar lipid-enriched fraction composition in a stable form with maximized functionality.
본 발명에 따르면 높은 인지질 함량을 지니고, 기존 밀크 레시틴(버터 유래)에 대비하여 간편한 음용성을 갖는 식품을 제조할 수 있으며, 특히 모유에 가까운 분유 제품을 제조할 수 있다. 또한, 장내 건강 개선 용도를 갖는 의약품을 제조할 수 있다.According to the present invention, it is possible to produce foods having a high phospholipid content and easy to drink compared to existing milk lecithin (derived from butter), and in particular, powdered milk products close to breast milk. In addition, pharmaceuticals with intestinal health improvement applications can be prepared.
도 1은 유청 유래 극성지질 농축 분획과 버터 유래 극성지질(BPL) 농축 분획의 차이를 나타낸 것이다. 유청 유래 극성지질 농축 분획은 5℃에서 균질한 고체 상태이고, 60℃에서 균질한 오일상 액체 상태이나, 버터 유래 극성지질 농축 분획은 상분리가 관찰되었다.
도 2는 실시예 2의 유청 유래 극성지질 농축 분획의 당 함량을 고성능 액체크로마토그래피로 분석한 결과이다.
도 3은 실시예 2의 유청 유래 극성지질 농축 분획의 인지질 함량을 고성능 액체 크로마토그래피로 분석한 결과이다.
도 4는 실시예 2의 유청 유래 극성지질 농축 분획(좌측)과 밀크 중성지질(우측)의 수상(Water phase) 분산 상태를 비교한 것이다.
도 5는 실시예 2의 유청 유래 극성지질 농축 분획(좌측)과 밀크 중성지질(우측)의 유상(Oil phase) 분산 상태를 비교한 것이다.
도 6은 유청 유래 극성지질 농축 분획의 항염증 효과를 나타낸 것이다.1 shows the difference between a whey-derived polar lipid enriched fraction and a butter-derived polar lipid (BPL) enriched fraction. The whey-derived polar lipid-enriched fraction was in a homogeneous solid state at 5°C and in a homogeneous oil-like liquid state at 60°C, but phase separation was observed in the butter-derived polar lipid-enriched fraction.
2 is a result of analyzing the sugar content of the whey-derived polar lipid enriched fraction of Example 2 by high-performance liquid chromatography.
3 is a result of analyzing the phospholipid content of the whey-derived polar lipid enriched fraction of Example 2 by high-performance liquid chromatography.
Figure 4 is a comparison of the water phase (Water phase) dispersion state of the whey-derived polar lipid concentrated fraction (left) and milk neutral lipid (right) of Example 2.
Figure 5 is a comparison of the oil phase (Oil phase) dispersion state of the whey-derived polar lipid enriched fraction (left) and milk neutral lipid (right) of Example 2.
Figure 6 shows the anti-inflammatory effect of the whey-derived polar lipid enriched fraction.
이하, 본 발명에 대하여 설명한다.Hereinafter, the present invention will be described.
종래 농축 인지질 조성물의 제조방법은 필연적으로 유당, 카제인 등의 비지질 성분을 다량 함유하게 되어, 극성지질을 높은 함량으로 농축 시 극성지질과 비극성지질, 그리고 수성 성분이 서로 부조화하여 층분리 및 침전 등이 일어나 흐름성이 나쁘고, 생산단가 또한 비싼 문제가 있었다.Conventional methods for producing concentrated phospholipid compositions inevitably contain a large amount of non-lipid components such as lactose and casein. When polar lipids are concentrated to a high content, polar lipids, non-polar lipids, and aqueous components are inconsistent with each other, resulting in layer separation and precipitation. There was a problem that the flow rate was bad and the production cost was also high.
이에, 본 발명자들은 버터유 대신 유청에 주정 추출 공정을 적용함으로써 단일상의 극성지질 농축물을 제조하여 층분리 및 침전 등을 방지하고 우수한 흐름성을 확보할 수 있는 극성지질 농축 조성물을 얻을 수 있음을 알아내었다. 본 발명은 이에 기초한 것이다.Accordingly, the present inventors have prepared a single-phase polar lipid concentrate by applying an alcohol extraction process to whey instead of butter oil to prevent layer separation and precipitation, and to obtain a polar lipid concentrate composition capable of securing excellent flowability. I figured it out. The present invention is based on this.
본 발명은 농축 유청 단백질을 물을 포함하는 주정으로 처리하여 얻어진 분획으로부터 유래하는 단일상의 조성물에 관한 것이다.The present invention relates to a single-phase composition derived from a fraction obtained by treating whey protein concentrate with an alcohol containing water.
본 발명에서, “단일상의 조성물”은 “총 지질의 함량이 조성물의 건조물 중량을 기준으로 90 중량% 이상”인 것을 의미한다.In the present invention, "single phase composition" means "the total lipid content is 90% by weight or more based on the dry weight of the composition".
본 발명의 용어 “농축 유청 단백질”은 유청에 이온교환식 필터링, 울트라 필터링, 마이크로 필터링 등의 방법을 적용하여 비단백성분을 제거함으로써 양질의 유청 단백질을 농축시킨 것을 말한다.The term "concentrated whey protein" of the present invention refers to high-quality whey protein concentrated by removing non-protein components by applying methods such as ion exchange filtering, ultra filtering, and micro filtering to whey.
본 발명의 용어“분획”은, 혼합되지 않는 둘 이상의 용매에 추출대상 물질을 침지시켜 추출대상 물질을 둘 이상의 용매층으로 추출함으로써 얻어지는 추출물의 형태를 의미한다.The term "fraction" of the present invention refers to the form of an extract obtained by immersing a substance to be extracted in two or more immiscible solvents and extracting the substance to be extracted with two or more solvent layers.
본 발명에서, 유청은 우유로 치즈 생산시 카제인과 분리되는 유당, 유청단백, 광물질 등을 말한다.In the present invention, whey refers to lactose, whey proteins, minerals, and the like that are separated from casein in milk cheese production.
본 발명에서, 유청은 감성 유청(Sweet whey) 또는 산성 유청(Acid whey)일 수 있다.In the present invention, the whey may be sweet whey or acid whey.
본 발명에서, 유청단백질은 치즈제조나 카세인생산 시 분리되어 나오는 단백질, 유당, 무기질, 비타민, 무기성분 등을 함유하는 액상 부산물을 말한다.In the present invention, whey protein refers to a liquid by-product containing protein, lactose, minerals, vitamins, and inorganic components that are separated during cheese production or casein production.
본 발명의 조성물은 유지방구막 구성성분 중 극성 지질 성분인 인지질의 함량이 총 지질 중량을 기준으로 35 중량% 이상이다,In the composition of the present invention, the content of phospholipid, which is a polar lipid component, is 35% by weight or more based on the total weight of lipids among the components of the milk fat membrane.
본 발명에서, 극성 지질 성분으로서 인지질은 포스파티딜에탄올아민(PE), 포스파티딜세린(PS), 포스파티딜콜린(PC), 스핑고미엘린(SM), 다른 인지질을 의미한다.In the present invention, phospholipids as polar lipid components refer to phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylcholine (PC), sphingomyelin (SM), and other phospholipids.
본 발명의 조성물에서 인지질은 포스파티딜콜린, 포스파티딜에탄올아민 및 스핑고미엘린을 포함하고, 포스파티딜콜린 1 중량부에 대하여 포스파티딜에탄올아민 0.5 내지 1.5 중량부, 스핑고미엘린 0.5 내지 1.5 중량부로 포함하는 것이 바람직하다.In the composition of the present invention, the phospholipids include phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin, and preferably include 0.5 to 1.5 parts by weight of phosphatidylethanolamine and 0.5 to 1.5 parts by weight of sphingomyelin based on 1 part by weight of phosphatidylcholine.
상기 조성물은, 조성물의 건조물 중량을 기준으로 1.35 중량% 이하의 환원당을 더 포함할 수 있다. 바람직하게는, 조성물의 건조물 중량을 기준으로 0.01 내지 1.2 중량%의 환원당을 더 포함할 수 있다.The composition may further include a reducing sugar of 1.35% by weight or less based on the dry weight of the composition. Preferably, 0.01 to 1.2% by weight of a reducing sugar based on the dry weight of the composition may be further included.
본 발명에서, 환원당은 당분자의 알데히드기 또는 케톤기가 유리 또는 헤미아세탈형으로 존재하는 당을 말하며, 구체적으로 포도당, 과당, 자당, 맥아당 및 유당으로 이루어진 군으로부터 선택되는 환원당일 수 있다.In the present invention, reducing sugar refers to a sugar in which an aldehyde group or a ketone group of a sugar molecule exists in a free or hemiacetal form, and may specifically be a reducing sugar selected from the group consisting of glucose, fructose, sucrose, maltose, and lactose.
일 실시예에서, 본 발명의 유청 유래 극성지질 농축물은 환원당을 함유하지 않았다. 다른 실시예에서, 이러한 환원당을 함유하지 않는 유청 유래 극성지질 농축물에 유당을 1.2 중량%까지 첨가한 경우에 층분리가 발생하지 않음을 확인하였다(표 2 참조).In one embodiment, the whey-derived polar lipid concentrate of the present invention is free of reducing sugars. In another example, it was confirmed that layer separation did not occur when lactose was added up to 1.2% by weight to the whey-derived polar lipid concentrate containing no reducing sugar (see Table 2).
본 발명의 조성물은, 조성물의 건조물 중량을 기준으로 1 내지 10 중량%의 콜레스테롤을 더 포함할 수 있다.The composition of the present invention may further comprise 1 to 10% cholesterol by weight based on the dry weight of the composition.
본 발명의 조성물은, 조성물의 건조물 중량을 기준으로 1 내지 10 중량%의 단백질을 더 포함할 수 있다.The composition of the present invention may further comprise 1 to 10% by weight of protein based on the dry weight of the composition.
일 례로, 상기 조성물은, 조성물의 건조물 중량을 기준으로 0.01 내지 1.2 중량%의 환원당, 1 내지 10 중량%의 콜레스테롤, 및 1 내지 10 중량%의 단백질을 더 포함하는 것일 수 있다.In one example, the composition may further include 0.01 to 1.2% by weight of reducing sugar, 1 to 10% by weight of cholesterol, and 1 to 10% by weight of protein based on the dry weight of the composition.
본 발명에서, 주정은 전분질 원료 또는 당질 원료를 발효시켜 증류한 것이나 조주정을 증류한 것으로 희석하여 음료로 할 수 있는 에탄올을 말한다. In the present invention, alcohol refers to ethanol obtained by fermenting and distilling a starch raw material or a sugar raw material, or distilling crude alcohol and distilling it into a beverage.
상기 주정은 총 주정 중량을 기준으로 30 중량% 미만의 물을 포함하며, 바람직하게는 5 내지 15 중량%의 물을 포함한다. 즉, 본 발명에서 사용하는 주정의 도수(농도)는 85 내지 95%일 수 있다. 주정의 도수(농도)는 에탄올의 부피 농도이다. 주정의 도수는 혼합 전 에탄올의 부피를 혼합 후 에탄올 수용액의 부피로 나눈 값이다.The spirit contains less than 30% by weight of water, preferably 5 to 15% by weight of water, based on the total weight of spirits. That is, the alcohol content (concentration) used in the present invention may be 85 to 95%. The alcohol strength (concentration) is the volumetric concentration of ethanol. The alcohol content is the value obtained by dividing the volume of ethanol before mixing by the volume of the aqueous ethanol solution after mixing.
본 발명의 다른 측면은Another aspect of the present invention is
1) 유청액을 농축하여 농축 유청 단백질을 제조하는 단계; 1) Concentrating the whey liquid to produce concentrated whey protein;
2) 물을 포함하는 주정으로 상기 농축 유청 단백질을 처리한 다음 주정 용물과 주정 불용물로 분리하는 단계; 및2) treating the concentrated whey protein with water-containing alcohol and then separating into alcohol-soluble and alcohol-insoluble substances; and
3) 상기 주정 용물로부터 에탄올과 수분을 제거하여 유청 유래 극성지질 분획 농축물을 얻는 단계;를 포함하는 본 발명의 조성물의 제조방법을 제공한다.3) obtaining a whey-derived polar lipid fraction concentrate by removing ethanol and water from the alcohol solution;
상기 단계 1)은 유청액에 이온교환식 필터링, 울트라 필터링, 마이크로 필터링 등의 방법을 적용하여 유당, 무기질, 비타민, 무기성분 등의 비단백성분을 제거하여 조 유청 단백질액을 제조하는 단계를 포함할 수 있다.Step 1) may include preparing a crude whey protein liquid by removing non-protein components such as lactose, minerals, vitamins, and inorganic components by applying methods such as ion exchange filtering, ultra filtering, and micro filtering to the whey liquid. can
본 발명의 일 실시예에서, 유청액에 이온 교환식 필터링을 적용시켜 단백질의 함량을 90% 이상으로 농축시켰다. In one embodiment of the present invention, the whey was subjected to ion exchange filtering to concentrate the protein content to greater than 90%.
상기 단계 1)은 상기 조 유청 단백질액을 분자량 10,000(MWCO, Molecular weight cut off range) 이하로 한외여과하여 여과 여액과 잔류물로 분리하여 농축 유청 단백질을 제조하는 단계를 포함할 수 있다.Step 1) may include ultrafiltration of the crude whey protein liquid to a molecular weight of 10,000 (MWCO, Molecular weight cut off range) or less, and separation into a filtrate and a residue to prepare concentrated whey protein.
상기 단계 2)에서 주정 처리는 농축 유청 단백질에 농축 유청 단백질의 중량 대비 3 내지 10 배수 중량의 주정을 혼합하고 5 내지 80℃, 바람직하게는 20 내지 45℃에서 0.5 내지 12시간 동안 추출하는 단계인 것이 바람직하다.In step 2), the alcohol treatment is a step of mixing concentrated whey protein with 3 to 10 times the weight of concentrated whey protein and extracting at 5 to 80 ° C, preferably 20 to 45 ° C for 0.5 to 12 hours. it is desirable
상기 단계 2)에서 물을 포함하는 주정으로 농축 유청 단백질을 처리 시 극성 차이에 의해 주정 용물과 주정 불용물로 분리된다.In the above step 2), when the concentrated whey protein is treated with water-containing alcohol, it is separated into an alcohol-soluble substance and an alcohol-insoluble substance due to a difference in polarity.
상기 단계 2)에서 주정은 총 주정 중량을 기준으로 30 중량% 미만의 물을 포함하며, 바람직하게는 5 내지 15 중량%의 물을 포함한다. 즉, 본 발명에서 주정의 도수는 85 내지 95%일 수 있다.In step 2), the alcohol contains less than 30% by weight of water, preferably 5 to 15% by weight of water, based on the total weight of alcohol. That is, in the present invention, the alcohol content may be 85 to 95%.
상기 단계 2)는 이후에 주정 처리 후에 30 내지 50℃에서 정치하여 중성지질을 제거하는 단계를 포함할 수 있다.Step 2) may include the step of removing neutral lipids by standing at 30 to 50 ° C. after the alcohol treatment.
본 발명의 조성물은 온도에 구애받지 않고 상분리가 일어나지 않는 단일상의 콜로이드로 존재할 수 있다. 본 발명의 조성물은 비극성 유기용제인 헥산 및 톨루엔에 모두 용해되며, 불용해물의 함량이 3 중량% 미만이다.The composition of the present invention may exist as a single-phase colloid that does not undergo phase separation regardless of temperature. The composition of the present invention is soluble in both hexane and toluene, which are non-polar organic solvents, and the content of insoluble matter is less than 3% by weight.
또한, 본 발명의 조성물은 우유의 관능적 특성을 유지하는 영유아용 식품, 특수용도 식품, 커피음료 등에 유화 및 관능강화 용도로 사용될 수 있다.In addition, the composition of the present invention can be used for emulsifying and sensory enhancing purposes such as foods for infants and young children, foods for special purposes, and coffee drinks that maintain the sensory characteristics of milk.
본 발명의 일 구체예에서, 상기 조성물은 장내 건강 개선용 조성물일 수 있다. 구체적으로, 장내 유해 미생물 생장 억제, 장내 유익균 성장 촉진 및 장내 상피세포 염증 완화 중 적어도 한 가지 이상의 용도로 사용되는 조성물일 수 있다.In one embodiment of the present invention, the composition may be a composition for improving intestinal health. Specifically, the composition may be used for at least one of inhibiting the growth of harmful microorganisms in the intestine, promoting the growth of beneficial bacteria in the intestine, and alleviating inflammation of intestinal epithelial cells.
본 발명의 일 시험예에서, 본 발명의 유청 유래 극성지질 농축물을 염증이 유발된 대식세포에 처리한 결과, 농도가 10, 100 μg/㎖인 경우 염증유발인자 IL-6의 분비량이 감소되었다(도 6).In one test example of the present invention, as a result of treating inflamed macrophages with the whey-derived polar lipid concentrate of the present invention, the secretion of the proinflammatory factor IL-6 was reduced when the concentration was 10 or 100 μg/ml. (Fig. 6).
또한, 본 발명의 일 실시예에서, 본 발명의 조성물은 팔라듐 혹은 니켈 촉매를 사용하여 수소 가압 환경 하에서 수소 첨가함으로써 요오드가가 10 이하인 건조 분획물이 될 수 있다.In addition, in one embodiment of the present invention, the composition of the present invention may be a dry fraction having an iodine value of 10 or less by adding hydrogen under a hydrogen pressurized environment using a palladium or nickel catalyst.
상기 분획물은 해당 수소첨가 과정을 거친 후 화장품 용도로 사용할 수 있다.The fraction can be used for cosmetic purposes after undergoing the corresponding hydrogenation process.
본 발명의 일 실시예에서, 본 발명의 조성물은 어유, 조류, 식물성 유래의 다가불포화 지방산에 0.1 내지 50 중량%로 혼합하여 산화방지 용도로 사용될 수 있다.In one embodiment of the present invention, the composition of the present invention may be used for antioxidant purposes by mixing 0.1 to 50% by weight with fish oil, algae, and vegetable-derived polyunsaturated fatty acids.
또한, 본 발명의 일 실시예에서, 본 발명의 조성물은 미엘린화 촉진 인지기능 개선 및 수면의 질 개선 생리활성을 나타낼 수 있다.In addition, in one embodiment of the present invention, the composition of the present invention may exhibit physiological activities of promoting myelination, improving cognitive function, and improving sleep quality.
또한, 본 발명의 일 실시예에서, 본 발명의 조성물은 화장품에 마이셀 및 리포좀화 유화 용도로 사용될 수 있다.In addition, in one embodiment of the present invention, the composition of the present invention can be used for micelle and liposomal emulsification purposes in cosmetics.
또한, 본 발명의 일 실시예에서, 본 발명의 조성물은 영유아용 식품, 특수용도 식품 및 커피음료에 유화 및 관능강화 용도로 사용될 수 있다.In addition, in one embodiment of the present invention, the composition of the present invention can be used for emulsifying and sensory enhancing purposes in foods for infants and young children, special purpose foods, and coffee beverages.
또한, 본 발명의 조성물은 식품용 조성물일 수 있다. 상기 식품은 크림, 요구르트, 음용 요구르트, 치즈, 치즈 스프레드, 유제품, 스프, 제과 및 제빵 생산물과 같은 제품으로 이루어지는 군으로부터 선택되는 것일 수 있다.In addition, the composition of the present invention may be a composition for food. The food may be selected from the group consisting of products such as cream, yogurt, beverage yogurt, cheese, cheese spread, dairy products, soups, confectionery and bakery products.
또한, 본 발명의 조성물은 화장품용 조성물일 수 있다.In addition, the composition of the present invention may be a cosmetic composition.
또한. 본 발명의 조성물은 장내 건강 개선용 약학적 조성물일 수 있다. 상기 조성물은 장내 건강 개선용 의약품에 사용될 수 있다.also. The composition of the present invention may be a pharmaceutical composition for improving intestinal health. The composition can be used in pharmaceuticals for improving intestinal health.
이하, 실시예 및 시험예를 개시하여 본 발명을 더욱 상세하게 설명한다. 실시예 및 시험예에 있어서 “%”는 특별히 지정하지 않는 한 “중량%”를 의미하는 것으로 한다.Hereinafter, the present invention will be described in more detail by disclosing examples and test examples. In Examples and Test Examples, “%” means “% by weight” unless otherwise specified.
실시예 1Example 1
치즈 제조 부산물로 수득한 유청액을 고형분 기준 6 내지 7%까지 농축 후 이를 분자량 10,000 kd로 한외여과하여 여과 여액과 잔류물로 분리하였다. 분리된 잔류물을 다시 농축 및 분무건조하여 농축 유청 단백질을 제조한 후 농축 유청 단백질의 중량 대비 6 배수 중량의 주정(95% 도수)을 혼합하고 25℃에서 1시간 동안 추출한 다음, 주정에 용해되지 않는 성분(주정 불용물)들을 제거한 다음, 주정에 용해되는 성분(주정 용물)들로부터 에탄올과 수분을 제거하여 유청 유래 극성지질 농축물을 얻었다.The whey liquid obtained as a by-product of cheese manufacturing was concentrated to 6-7% on a solid basis, and then ultrafiltered with a molecular weight of 10,000 kd to separate the filtrate and the residue. The separated residue is concentrated and spray-dried again to produce concentrated whey protein, and then mixed with alcohol (95% alcohol content) six times the weight of the concentrated whey protein, extracted at 25 ° C for 1 hour, and then not dissolved in alcohol. Components (insoluble in alcohol) were removed, and then ethanol and water were removed from components (insoluble in alcohol) to obtain a whey-derived polar lipid concentrate.
얻은 유청 유래 극성지질 농축물에 대해 클로로포름, 메탄올, 아세트산을 구배 이동상으로 한 고성능 액체크로마토그래피 분석을 수행하여 콜레스테롤 5 중량%, 총 인지질 함량 28 중량%(PC 9 중량%, PE 8 중량%, SM 9 중량% 등)을 확인하였다.The obtained whey-derived polar lipid concentrate was subjected to high-performance liquid chromatography analysis using chloroform, methanol, and acetic acid as a gradient mobile phase to obtain 5 wt% cholesterol and 28 wt% total phospholipid content (PC 9 wt%, PE 8 wt%, SM 9% by weight, etc.) was confirmed.
또한, 킬달 분석법을 수행하여 단백질 함량이 5 중량%임을 확인하였다.In addition, Kjeldahl analysis was performed to confirm that the protein content was 5% by weight.
구체적으로, 얻은 유청 유래 극성지질 농축물 시료에 단백질 분해촉진제와 황산을 넣은 후, Foss Tecator Digestor Auto 20, Foss Tecator Scrubber로 420℃에서 90분 동안 분해시켰다. 분해 후 Foss Kjeltec 8400, Foss Kjeltec Sampler 8420으로 분석하였다. Specifically, after adding a proteolytic agent and sulfuric acid to the obtained whey-derived polar lipid concentrate sample, it was digested at 420 ° C. for 90 minutes with Foss Tecator Digestor Auto 20 and Foss Tecator Scrubber. After disassembly, it was analyzed with Foss Kjeltec 8400 and Foss Kjeltec Sampler 8420.
얻은 유청 유래 극성지질 농축물에 대해 아세토니트릴(80%)을 구배 이동상으로 한 고성능 액체크로마토그래피 분석(유속: 1.0ml/min, 35℃)을 30분 동안 수행하였다. 그 결과 과당, 포도당, 자당, 맥아당, 유당 등이 포함되지 않음을 확인하였다(도 2 참조) High-performance liquid chromatography analysis (flow rate: 1.0 ml/min, 35° C.) using acetonitrile (80%) as a gradient mobile phase was performed on the whey-derived polar lipid concentrate obtained for 30 minutes. As a result, it was confirmed that fructose, glucose, sucrose, maltose, lactose, etc. were not included (see FIG. 2).
또한 31P-NMR 분석을 수행하여 상기 인지질 함량을 재확인하였다.In addition, 31 P-NMR analysis was performed to reconfirm the phospholipid content.
비교예 1Comparative Example 1
버터유 제조 과정으로부터 유래된 지질 함유 버터밀크 분말을 95% 도수의 주정으로 처리하여, 주정 용물과 불용물로 분리한 다음, 주정 용물로부터 에탄올과 수분을 제거하여 버터 유래 극성지질 농축물을 얻었다. Lipid-containing buttermilk powder derived from the butter oil manufacturing process was treated with 95% alcohol, separated into alcohol and insoluble matter, and then ethanol and water were removed from the alcohol to obtain a butter-derived polar lipid concentrate.
시험예 1 Test Example 1
실시예 1의 유청 유래 극성지질 농축물과 비교예 1의 버터 유래 극성지질 농축물의 조지방 함량, 총 지질 함량, 및 유당 등 환원당 함량을 평가하여 그 결과를 하기 표 1에 나타냈다.The crude fat content, total lipid content, and reducing sugar content such as lactose of the whey-derived polar lipid concentrate of Example 1 and the butter-derived polar lipid concentrate of Comparative Example 1 were evaluated, and the results are shown in Table 1 below.
상기 표에서 보는 바와 같이, 본 발명의 유청 유래 극성지질 농축물은 총지질 함량이 96 중량%이고, 환원당이 불검출되었다. As shown in the table above, the whey-derived polar lipid concentrate of the present invention had a total lipid content of 96% by weight and no reducing sugar was detected.
시험예 2Test Example 2
실시예 1의 유청 유래 극성지질 농축물로 이루어진 샘플 #1~#10에 대해 하기 표 2에 기재된 바와 같이 유당 함량을 달리하여 첨가하여, 50℃로 가온교반하였다. 이 후 실온으로 냉각하여 단일상 여부를 판정하여 그 결과를 하기 표 2에 나타냈다.Samples #1 to #10 consisting of the whey-derived polar lipid concentrate of Example 1 were added with different lactose contents as shown in Table 2 below, and heated and stirred at 50°C. Thereafter, it was cooled to room temperature to determine whether or not it was a single phase, and the results are shown in Table 2 below.
첨가량
(중량%)lactose
Amount added
(weight%)
상기 표 2의 결과로부터, 조성물이 유당을 약 1.2 중량%까지 포함할 경우 층분리가 일어나지 않음을 알 수 있다.From the results of Table 2, it can be seen that layer separation does not occur when the composition contains up to about 1.2% by weight of lactose.
실시예 2Example 2
실시예 1의 유청 유래 극성지질 농축물을 물을 포함한 93% 주정으로 처리한 후 30 내지 50℃에서 정치하여 중성지질 및 일부 복합지질을 추가로 제거하였다(고형분 15중량 %).The whey-derived polar lipid concentrate of Example 1 was treated with 93% alcohol containing water, and then left at 30 to 50 ° C. to further remove neutral lipids and some composite lipids (solid content: 15% by weight).
고성능 액체크로마토그래피를 수행하여 총 인지질 함량이 50 중량%(PC 18 중량%, PE 12 중량%, SM 18 중량% 등)임을 확인하였다(도 3). High-performance liquid chromatography was performed to confirm that the total phospholipid content was 50 wt% (PC 18 wt%, PE 12 wt%, SM 18 wt%, etc.) (FIG. 3).
또한, 킬달 분석법을 수행하여 단백질 함량이 5 중량%임을 확인하고, 탄수화물 분석을 통해 유당 및 포도당 등이 포함되지 않음을 확인하였다. In addition, Kjeldahl analysis was performed to confirm that the protein content was 5% by weight, and carbohydrate analysis confirmed that lactose and glucose were not included.
시험예 3: 추출 분획 특성에 따른 극성지질 함량 변화Test Example 3: Polar lipid content change according to extraction fraction characteristics
실시예 1의 유청 유래 극성지질 농축물을 물을 포함한 주정으로 처리함에 있어 주정의 도수(%) 및 고형분 함량(중량%)을 변화시켜 가면서 이에 따른 극성지질의 함량 변화를 측정하여 그 결과를 하기 표 3에 나타냈다.In treating the whey-derived polar lipid concentrate of Example 1 with alcohol containing water, the change in the polar lipid content was measured while changing the alcohol content (%) and solid content (% by weight) of the alcohol, and the results are shown below Table 3 shows.
8.5 중량%solid content
8.5% by weight
12 중량%solid content
12% by weight
15 중량%solid content
15% by weight
16.6 중량%solid content
16.6% by weight
상기 표에서 PL은 PC, PE, SM, PS 및 PI을 합한 인지질의 총칭이고, PC/PE/SM은 지표되는 인지질이다.In the table above, PL is a generic term for phospholipids including PC, PE, SM, PS, and PI, and PC/PE/SM is an indexed phospholipid.
상기 표에서 보는 바와 같이, 극성지질 농축물을, 85 내지 95%로 주정의 도수를 변화시키고 8.5 내지 16.6 중량%로 고형분 함량을 변화시켜 가면서 주정으로 처리한 결과, 인지질의 함량이 최소 35 중량%인 것으로 나타났다. As shown in the table above, the polar lipid concentrate was treated with alcohol while changing the alcohol content from 85 to 95% and the solid content from 8.5 to 16.6% by weight, resulting in a phospholipid content of at least 35% by weight appeared to be
상기 표에서 보는 바와 같이, 우유 성분 중 지표 성분인 인지질 함량은 주정의 도수(%) 및 고형분 함량(중량%)에 따라 변화하였다.As shown in the table above, the phospholipid content, which is an index component among milk components, varied according to the alcohol content (%) and solid content (% by weight).
실시예 3Example 3
실시예 2의 유청 유래 극성지질 농축물을 아세톤에 침지하여, 가온하며 용해시킨 후 냉각하여 재결정화시켰다. 결정화물과 아세톤액을 분리한 후 결정화물만 따로 수득한 후 고성능 액체크로마토그래피 분석하여 총 인지질 함량 80 중량%인 분획물임을 확인하였다.The whey-derived polar lipid concentrate of Example 2 was immersed in acetone, dissolved while heating, and recrystallized by cooling. After separating the crystals from the acetone solution, only the crystals were obtained separately, and then analyzed by high-performance liquid chromatography to confirm that the fractions had a total phospholipid content of 80% by weight.
시험예 4Test Example 4
실시예 2의 유청 유래 극성지질 농축물과, 밀크 중성 지질을 각각 물 및 MCT 오일에 1%(v/v) 농도로 40℃에서 분산시켰다. The whey-derived polar lipid concentrate of Example 2 and milk neutral lipids were dispersed in water and MCT oil at a concentration of 1% (v/v) at 40°C, respectively.
도 4에 실시예 2의 유청 유래 극성지질 농축 분획과 밀크 중성지질의 수상(Water phase) 분산 상태를 나타내고, 도 5는 실시예 2의 유청 유래 극성지질 농축 분획과 밀크 중성지질의 유상(Oil phase) 분산 상태를 나타내었다. Figure 4 shows the dispersion state of the whey-derived polar lipid concentrated fraction and milk neutral lipids of Example 2, and Figure 5 shows the oil phase dispersion of the whey-derived polar lipid concentrated fraction and milk neutral lipids of Example 2. state was indicated.
그 결과 실시예 2의 유청 유래 극성지질 농축물은 물 및 MCT 오일에서 유백색의 유화액을 형성하고, 밀크 중성 지질은 상 분리가 일어난 것을 확인하였다.As a result, it was confirmed that the whey-derived polar lipid concentrate of Example 2 formed a milky white emulsion in water and MCT oil, and phase separation occurred in the milk neutral lipid.
또한 실시예 2의 유청 유래 극성지질 농축물을 글리세린 및 물에 80℃로 가온하며 용해시킨 후 1,000rpm 호모믹서 처리한 다음 2,000 bar 고압유화를 2회 적용하여 투명한 성상의 유화액을 수득하였다. 상기 유화액을 Zetapal 기기로 제타전위 및 입도를 분석한 결과, 제타전위값은 -1.8, 입도는 100~150 nm로 나타났다. In addition, the whey-derived polar lipid concentrate of Example 2 was dissolved in glycerin and water while heating at 80 ° C, treated with a 1,000 rpm homomixer, and then 2,000 bar high pressure emulsification was applied twice to obtain a transparent emulsion. As a result of analyzing the zeta potential and particle size of the emulsion with a Zetapal instrument, the zeta potential value was -1.8 and the particle size was 100 to 150 nm.
실시예 4Example 4
실시예 2의 유청 유래 극성지질 농축물을 주정으로 용해시킨 후 Pd/C 촉매를 농축 분획물의 백분율 중량비 대비 10% 첨가한 후 60℃, 30bar, 수소환경 하에서 교반하여 수소를 첨가하였다. After dissolving the whey-derived polar lipid concentrate of Example 2 in alcohol, a Pd/C catalyst was added in an amount of 10% based on the weight percentage of the concentrated fraction, followed by stirring under a hydrogen environment at 60° C. and 30 bar to add hydrogen.
0.2 ㎛ 멤브레인 필터로 여과하여 Pd/C 촉매를 제거하고 10℃로 냉각한 후 Whatman No.2 여과지로 여과하여 여액과 고형분으로 분리하였다. 고형분을 감압농축기에서 감압농축하여 에탄올과 수분을 제거한 후 위지(Wijs) 솔루션으로 요오드가 분석을 수행한 결과, 요오드가가 1이며, 색도와 냄새가 제거된 분획물을 얻었다.The Pd/C catalyst was removed by filtration with a 0.2 μm membrane filter, cooled to 10° C., and then filtered with Whatman No.2 filter paper to separate the filtrate and the solid content. The solid content was concentrated under reduced pressure in a vacuum concentrator to remove ethanol and water, and then iodine value was analyzed using a Wijs solution. As a result, a fraction having an iodine value of 1 and color and odor removed was obtained.
시험예 5Test Example 5
실시예 2의 유청 유래 극성지질 농축물을 생리식염수에 분산하여, 염증이 유발된 대식세포에 처리하여 대식세포에 미치는 영향, 즉, 염증유발인자 IL-6 분비 감소 효과, 및 염증 완화 효과를 조사하였다.The whey-derived polar lipid concentrate of Example 2 was dispersed in physiological saline and treated with inflamed macrophages to investigate the effect on macrophages, that is, the effect of reducing the secretion of the pro-inflammatory factor IL-6 and the effect of alleviating inflammation. did
그 결과, 도 6에서 보는 바와 같이, 실시예 2의 유청 유래 극성지질 농축물의 농도가 10, 100 μg/㎖인 경우 염증유발인자 IL-6의 분비량이 감소되었음을 알 수 있다.As a result, as shown in FIG. 6, it can be seen that the secretion of the pro-inflammatory factor IL-6 was reduced when the concentration of the whey-derived polar lipid concentrate of Example 2 was 10 or 100 μg/ml.
Claims (14)
물을 포함하는 주정으로 상기 농축 유청 단백질을 처리하여 얻어진 주정 용물을 포함하는 분획으로부터 유래하고,
총 지질의 함량이, 조성물의 건조물 중량을 기준으로 90 중량% 이상이고,
인지질 함량이 총 지질 중량을 기준으로 35 중량% 이상이고,
조성물의 건조물 중량을 기준으로 1.35 중량% 이하의 환원당을 더 포함하여 층분리가 일어나지 않고,
상기 환원당은 포도당, 과당, 자당, 맥아당 및 유당으로 이루어지는 군으로부터 선택되는 적어도 하나의 당인 것인 유청 유래 극성지질 농축 분획 조성물.As a single phase composition derived from whey protein concentrate,
Derived from a fraction containing spirits obtained by treating the whey protein concentrate with spirits containing water;
The total lipid content is at least 90% by weight based on the dry weight of the composition,
The phospholipid content is at least 35% by weight based on the total lipid weight,
Layer separation does not occur by further including a reducing sugar of 1.35% by weight or less based on the dry weight of the composition,
The reducing sugar is at least one sugar selected from the group consisting of glucose, fructose, sucrose, maltose and lactose, whey-derived polar lipid concentrated fraction composition.
2) 물을 포함하는 주정으로 상기 농축 유청 단백질을 처리한 다음 주정 용물과 주정 불용물로 분리하는 단계; 및
3) 상기 주정 용물로부터 에탄올과 수분을 제거하여 유청 유래 극성지질 분획 농축물을 얻는 단계;를 포함하되,
상기 단계 2)에서 농축 유청 단백질은 농축 유청 단백질의 중량 대비 3 내지 10 배수 중량의, 물을 포함하는 주정과 혼합되어 5 내지 80℃에서 0.5 내지 12 시간 동안 추출을 진행하여 주정 용물과 주정 불용물로 분리되는 것인
제1항의 유청 유래 극성지질 농축 분획 조성물의 제조방법.1) Concentrating the whey liquid to produce concentrated whey protein;
2) treating the concentrated whey protein with water-containing alcohol and then separating into alcohol-soluble and alcohol-insoluble substances; and
3) obtaining a whey-derived polar lipid fraction concentrate by removing ethanol and water from the alcohol solution;
In step 2), the concentrated whey protein is mixed with water-containing alcohol, which is 3 to 10 times the weight of the concentrated whey protein, and extracted for 0.5 to 12 hours at 5 to 80 ° C. which is separated by
A method for producing the whey-derived polar lipid-enriched fraction composition of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230024599A KR102693099B1 (en) | 2019-12-03 | 2023-02-23 | Composition enriched in polar lipids fraction from whey and uses thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190159321A KR20210069460A (en) | 2019-12-03 | 2019-12-03 | Composition enriched in polar lipids fraction from whey and uses thereof |
| KR1020230024599A KR102693099B1 (en) | 2019-12-03 | 2023-02-23 | Composition enriched in polar lipids fraction from whey and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190159321A Division KR20210069460A (en) | 2019-12-03 | 2019-12-03 | Composition enriched in polar lipids fraction from whey and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230035281A true KR20230035281A (en) | 2023-03-13 |
| KR102693099B1 KR102693099B1 (en) | 2024-08-08 |
Family
ID=76376503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190159321A KR20210069460A (en) | 2019-12-03 | 2019-12-03 | Composition enriched in polar lipids fraction from whey and uses thereof |
| KR1020230024599A KR102693099B1 (en) | 2019-12-03 | 2023-02-23 | Composition enriched in polar lipids fraction from whey and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190159321A KR20210069460A (en) | 2019-12-03 | 2019-12-03 | Composition enriched in polar lipids fraction from whey and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (2) | KR20210069460A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116322345A (en) * | 2020-12-18 | 2023-06-23 | 索路思生物技术有限公司 | Polar lipid concentrate fraction compositions derived from whey and uses thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003070669A (en) | 2001-09-07 | 2003-03-11 | Kvk Corp | Elbow attaching structure for hand-shower |
| WO2003071875A1 (en) | 2002-02-21 | 2003-09-04 | Land O'lakes, Inc. | Method of preparing a milk polar lipid enriched concentrate and a sphingolipid enriched concentrate |
| WO2007123424A1 (en) * | 2006-04-20 | 2007-11-01 | Owen John Catchpole | Process for separating lipid materials |
| WO2008009636A1 (en) | 2006-07-17 | 2008-01-24 | S.A. Corman | Milk ingredient enriched in polar lipids and uses thereof |
| KR20080066726A (en) * | 2005-09-30 | 2008-07-16 | 유키지루시 뉴교 가부시키가이샤 | Powder being rich in milk-origin complex lipids |
| WO2009066685A1 (en) | 2007-11-19 | 2009-05-28 | Snow Brand Milk Products Co., Ltd. | Sense-improving agent |
| JP2012061012A (en) * | 2005-05-31 | 2012-03-29 | Arla Foods Amba | Phosphatidylserine enriched milk fraction for formulation of functional food |
| JP2014516565A (en) * | 2011-06-08 | 2014-07-17 | ネステク ソシエテ アノニム | Nutritional composition having exogenous milk fat globule membrane component |
| EP1814399B1 (en) | 2004-10-12 | 2016-05-18 | Fonterra Co-Operative Group Limited | Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production |
-
2019
- 2019-12-03 KR KR1020190159321A patent/KR20210069460A/en not_active IP Right Cessation
-
2023
- 2023-02-23 KR KR1020230024599A patent/KR102693099B1/en active IP Right Grant
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003070669A (en) | 2001-09-07 | 2003-03-11 | Kvk Corp | Elbow attaching structure for hand-shower |
| WO2003071875A1 (en) | 2002-02-21 | 2003-09-04 | Land O'lakes, Inc. | Method of preparing a milk polar lipid enriched concentrate and a sphingolipid enriched concentrate |
| EP1814399B1 (en) | 2004-10-12 | 2016-05-18 | Fonterra Co-Operative Group Limited | Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production |
| JP2012061012A (en) * | 2005-05-31 | 2012-03-29 | Arla Foods Amba | Phosphatidylserine enriched milk fraction for formulation of functional food |
| KR20080066726A (en) * | 2005-09-30 | 2008-07-16 | 유키지루시 뉴교 가부시키가이샤 | Powder being rich in milk-origin complex lipids |
| WO2007123424A1 (en) * | 2006-04-20 | 2007-11-01 | Owen John Catchpole | Process for separating lipid materials |
| WO2008009636A1 (en) | 2006-07-17 | 2008-01-24 | S.A. Corman | Milk ingredient enriched in polar lipids and uses thereof |
| WO2009066685A1 (en) | 2007-11-19 | 2009-05-28 | Snow Brand Milk Products Co., Ltd. | Sense-improving agent |
| JP2014516565A (en) * | 2011-06-08 | 2014-07-17 | ネステク ソシエテ アノニム | Nutritional composition having exogenous milk fat globule membrane component |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210069460A (en) | 2021-06-11 |
| KR102693099B1 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Conway et al. | Buttermilk: much more than a source of milk phospholipids | |
| RU2420083C2 (en) | Milk fractions enriched with phosphatidylserine for functional alimentation composition | |
| EP1814399B1 (en) | Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production | |
| Costa et al. | Use of ultrafiltration and supercritical fluid extraction to obtain a whey buttermilk powder enriched in milk fat globule membrane phospholipids | |
| JP5616066B2 (en) | Human lipid composition and methods for making and using the same | |
| NZ567130A (en) | Powder being rich in milk-origin complex lipids and method for production | |
| KR102693099B1 (en) | Composition enriched in polar lipids fraction from whey and uses thereof | |
| AU2007268967A1 (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
| Jukkola et al. | Effect of heat treatment and pH on the efficiency of micro-diafiltration for the separation of native fat globules from cream in butter production | |
| EP2346342B1 (en) | Method to separate lipids from cheese whey and fat-free whey protein product formed thereby | |
| US5762994A (en) | Obtention of protein and lipid compositions from fruit kernels | |
| WO2008016108A1 (en) | Agent for preventing infection | |
| US20230380445A1 (en) | Whey-derived polar lipids-concentrated fraction composition and use thereof | |
| Elías‐Argote et al. | Dairy ingredients containing milk fat globule membrane: description, composition, and industrial potential | |
| JP4559836B2 (en) | Method for producing a complex lipid-rich material and a complex lipid-rich material | |
| RU2417614C2 (en) | Infant food containing beta-whey | |
| KR20230111610A (en) | Novel cholesterol-rich milk lipid composition suitable for infant nutrition, manufacturing method and nutritional composition comprising said milk lipid composition | |
| US20210386083A1 (en) | Method for producing a phospholipid concentrate from a dairy composition | |
| CN104582508B (en) | A method for the preparation of a serum protein concentrate | |
| Gonzalez et al. | Advances in Milk Fractionation for Value Addition | |
| Gonzalez et al. | Advances in Milk Fractionation Addition for Value | |
| WO2024196981A1 (en) | Method for producing a plant-based food product | |
| AU2015227507B2 (en) | Method to separate lipids from cheese whey and fat-free whey protein product formed thereby | |
| WO2010026229A1 (en) | Composition richly containing polar lipid and method of manufacturing the same | |
| CN109198029A (en) | Sea-buckthorn bovine colostrum and its production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |